Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database
In total, 48.2% of French patients with SLE were treated with OCS in 2019, including 12.4% at a mean dose >5 mg/day, with an increased risk of OCS complications and a limited use of antimalarials, immunosuppressants or biologics. These results highlight the urgent need for the implementation of more robust OCS-sparing strategies in SLE.
Authors
- R. Todea
- Stephane Bouée (ORCID: https://orcid.org/0000-0001-6838-2680)
- Gabriel Thabut (ORCID: https://orcid.org/0000-0001-7218-7917)
- I. Bureau (ORCID: https://orcid.org/0000-0001-6879-6357)
- Blandine Vidal
- C. Fabry-Vendrand (ORCID: https://orcid.org/0000-0001-8786-7843)
- Laurent Arnaud (ORCID: https://orcid.org/0000-0002-8077-8394)
- Juliette Cottin
Institutions
- Inserm (FR)
- Cemka-Eval (France) (FR)
- AstraZeneca (France) (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- Université de Strasbourg (FR)
Publication Details
- Journal
- Lupus Science & Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/lupus-2024-001428
- Citations
- 7
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 11.68